Larvol Delta - BioAtlas-Mecbotamab-Vedotin-MecV-an-AXLtargeting-ADC-Demonstrates-a-Median-Overall-Survival-OS-of-215-months-in-Subtypes-of-Refractory-Soft-Tissue-Sarcomas

mecbotamab vedotin (BA3011) - BioAtla

https://www.globenewswire.com/news-release/2025/11/07/3183685/0/en/BioAtla-s-Mecbotamab-Vedotin-Mec-V-an-AXL-targeting-ADC-Demonstrates-a-Median-Overall-Survival-OS-of-21-5-months-in-Subtypes-of-Refractory-Soft-Tissue-Sarcomas.html

Nov 7, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next